AI CORNER: Chat GPT
Two Senior CMS Officials on "Saving Costs" - June 2026
MedCityNews, June 9, 2026 (Katie Adams): CMS Dr. Oz on Making Healthcare Affordable
https://medcitynews.com/2026/06/dr-oz-cms-healthcare-affordability/
MedCityNews, June 8, 2026 (Katie Adams): Casey Mulligan on Healthcare Cost Incentives
https://medcitynews.com/2026/06/hhs-affordability-healthcare-costs/
##
For experts, these two pieces in MedCityNews are less “two cost-control plans” than two different levels of the same policy stack. Oz is giving the CMS administrator’s operational/political affordability agenda: fraud, drugs, IT, prevention, deregulation. Mulligan is giving the HHS economist’s causal theory of cost growth: distorted incentives, especially Medicaid financing mechanics, propagate through the whole system.
Core thesis of each
Oz: CMS can make care more affordable by attacking visible sources of excess cost and friction: fraud, waste, drug prices, antiquated claims infrastructure, chronic disease burden, and regulatory overhead. His framework is program-administrative and public-facing: identify large “fixable” domains and mobilize CMS authority around them.
Mulligan: Healthcare costs are not primarily a coverage problem; they are an incentives problem. He wants policy analysis to separate health, healthcare, and insurance, and to ask who pays, who benefits, and what behaviors are induced. His concrete target is Medicaid provider taxes and state-directed payments, which he portrays as fiscal machinery that inflates spending and spills over into commercial premiums, wages, Medicare, and taxpayers.
Where Oz and Mulligan overlap
They overlap most strongly in diagnosis by incentives rather than entitlement expansion. Neither frames affordability as “more insurance coverage” or “larger subsidies.” Both emphasize that current financing and administrative structures generate avoidable cost.
They also overlap on patient control and information, though with different emphases. Oz’s app-library and interoperability discussion points toward consumer access, portability, and data liquidity. Mulligan’s version is more economic: patients need data, price transparency, genuine choices, and freedom to compare competing medical claims.
They share a deregulatory skepticism toward legacy systems. Oz criticizes quality-measurement burden and welcomes a 10-for-1 deregulatory mandate. Mulligan, as chief regulatory officer, focuses on regulatory impact analysis: measuring costs, benefits, distributional effects, and incentive consequences.
They also both imply that federal healthcare costs are embedded in cross-market systems. Oz says Medicare fraud alone could dramatically affect the trust fund. Mulligan says Medicaid payment games spill into commercial prices, employer premiums, wages, Medicare spending, and taxpayers. Both reject siloed accounting.
What is unique to Oz
Oz’s agenda is broader and more operational. His five buckets are:
Fraud, waste, and abuse — especially DME in South Florida, hospice clustering in Los Angeles, and personal care services employment in New York and California. His Covid-era point is politically important: emergency spending and weak tracking taught new actors that healthcare fraud was accessible.
Drug pricing reform — especially Most Favored Nation pricing, with a claimed $600 billion ten-year savings estimate, plus GLP-1 access for certain Medicare beneficiaries with obesity-related conditions at $50/month.
Technology modernization — replacing Medicare’s COBOL-based billing infrastructure with cloud systems, plus the Medicare App Library and data-sharing networks.
Preventive health and nutrition — especially obesity and chronic disease, nutrition education in medical schools, and revised dietary guidance.
Deregulation and measurement reform — less faith in quality-measure proliferation, more concern about administrative burden.
Oz is therefore speaking as an agency head trying to communicate a portfolio: enforcement, payment policy, IT modernization, prevention, and deregulation.
What is unique to Mulligan
Mulligan’s piece is narrower but more theoretically pointed. His distinctive contribution is the “supply-side health economics” frame: do not confuse insurance expansion with health improvement or cost reduction. He wants to analyze delivery-side incentives.
His most concrete policy target is Medicaid provider taxes plus supplemental/state-directed payments. The mechanism he describes is:
States tax hospitals, nursing homes, or managed-care plans; use the revenue to draw down federal matching dollars; then return funds to providers through supplemental or state-directed payments. Mulligan argues this is not benign fiscal plumbing. It changes provider incentives, increases the cost of delivering care, shifts resources, raises commercial prices and employer premiums, affects marketplace premiums and wages, and even spills into Medicare.
That is the more technical article. It is less about “CMS can modernize X” and more about “federal-state financing arbitrage creates systemwide price inflation.”
Do they disagree?
There is no direct contradiction in the excerpts. The articles are complementary, not adversarial.
The closest tension is one of emphasis:
Oz says major savings can come from fraud enforcement, drug pricing, modernization, prevention, and deregulation. Mulligan says the deeper affordability problem is incentive design, especially financing mechanisms that inflate provider payments and prices.
A second mild tension is that Oz’s agenda includes some expanded access/payment policy, such as cheaper GLP-1 access for Medicare beneficiaries with obesity-related conditions. Mulligan’s lens would ask whether that policy improves health enough to justify costs and what incentives it creates. But the excerpt does not show Mulligan criticizing GLP-1 coverage, and Oz frames it as affordability/access.
A third tension is philosophical: Oz’s prevention-and-nutrition discussion is clinician-population-health oriented; Mulligan’s is economist-incentive oriented. Oz talks about chronic disease burden and medical education. Mulligan talks about regulatory impact, price spillovers, and financing distortions. These are different explanatory languages, not contradictions.
Expert read: what this signals
Together, the articles suggest a Trump-era HHS/CMS affordability message built around five themes:
First, anti-fraud enforcement will be framed as trust-fund solvency policy, not just program integrity.
Second, drug pricing remains central, especially through international reference-pricing rhetoric.
Third, CMS modernization is being cast as cost policy, not merely IT housekeeping.
Fourth, chronic disease prevention is being absorbed into affordability policy, with nutrition and obesity as cost drivers.
Fifth, Medicaid financing reform may become one of the most consequential technical battlegrounds, because Mulligan is explicitly tying provider taxes and state-directed payments to commercial premium inflation, employer costs, wages, Medicare spending, and federal taxpayer exposure.
For a policy expert, Mulligan’s piece may be the more important tea leaf. Oz lists the visible agenda. Mulligan identifies a technically specific target with large distributional stakes: the provider-tax/supplemental-payment ecosystem. If HHS acts on that theory, hospitals, states, Medicaid managed care plans, and employer purchasers will all care deeply.
#
See an alternate summary by Claude Opus 4.8 here.
Prompt. Summarize these two articles for experts. Where do Oz and Mulligan overlap, where is each unique, do they ever disagree (contradict). # # # full text also here.
